0.00
-20.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About CannaPharmaRx
From its filings with the US Securities and Exchange Commission
CannaPharmaRx is based in Mountain View County and is incorporated in Delaware. Its shares trade on OTC under the ticker CPMD. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $1.4m and a net loss of $11.1m. At that date it held total assets of $7.0m and shareholders' equity of −$30.2m.
On January 6, 2022, we entered into a 20-year operating lease for the use of a 55,000 square foot facility located in Cremona, Alberta, Canada (the “Facility”). During 2022, we recommissioned the Facility into an indoor cannabis farm with 10 growing rooms and one drying and packing room. The Facility currently operates six of these growing rooms and one drying and packing room and plans to increase capacity over the next one to two years to open a second drying and packing room and to operate all 10 growing rooms. We received an operating license from Health Canada on December 9, 2022, and a cannabis license from the Canada Revenue Agency (“CRA”) on December 22, 2022, and commenced cannabis production during the year ended December 31, 2023.
We plan to grow by increasing our production capacity at the Facility to support sales of cannabis to the European markets, with a focus on Germany and Israel. To support this initiative, we intend to increase the number of growing rooms from six to 10 rooms over the next one to two years and to open a second drying and packing room, building and developing a sales network in Germany and Israel, and applying for European Union Good Manufacturing Practices (“EU-GMP”) certification. Currently, we are required to send our cannabis to a third-party European intermediary for packaging in compliance with EU-GMP standards. Once we receive the EU-GMP certification we will be able to remove this step from our delivery process and ship directly to countries within the European Union (“EU”), reducing overall costs and shipping timelines.
Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 29 Oct 1999
- Employees
- 26
- Website
- cannapharmarx.com ↗
- Head office
- 4439 TOWNSHIP RD 304, MOUNTAIN VIEW COUNTY, T0M 0R0
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Constantine NkafuInterim Chief Executive Officer, Director, since 2024$29,292
- Mr. Oliver FoesteChief Financial Officer$99,837
- Mr. Dominic ColvinDirector, since 2018$148,767
- Mr. Anthony PanekDirector
- Mr. Elliot ZemelDirector
- Mr. Richard OrmanIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CannaPharmaRx Inc is positioned as a leading player in the cannabis industry, with a strong market presence and brand reputation. The company has a diverse range of high-quality cannabis products, catering to various customer segments. This product diversity allows the company to capture a larger market share and maintain a competitive edge.
- CannaPharmaRx Inc has established strategic partnerships and collaborations, enabling it to expand its distribution network and reach more consumers. These partnerships provide access to new markets, enhancing the company's revenue potential and growth prospects.
Weaknesses
- One of the key weaknesses of CannaPharmaRx Inc is its heavy dependence on regulatory environments. The cannabis industry is subject to complex and evolving regulations, which may affect the company's operations and sales. Changes in legislation or restrictive regulations can pose challenges and impact the company's profitability.
- The company's reliance on external suppliers for raw materials and ingredients is another weakness. Supply chain disruptions or quality issues with suppliers could potentially hamper production and affect product availability.
Opportunities
- CannaPharmaRx Inc has an opportunity to capitalize on the increasing acceptance and legalization of cannabis products globally. By expanding its operations to new markets, the company can tap into a broader customer base and drive revenue growth.
- The growing trend towards the use of medical cannabis presents an opportunity for CannaPharmaRx Inc to develop innovative and specialized pharmaceutical-grade cannabis products. This can help the company establish itself as a leader in the medical cannabis market and further differentiate itself from competitors.
Threats
- Intense competition within the cannabis industry poses a threat to CannaPharmaRx Inc. As new players enter the market and existing competitors ramp up their efforts, the company must continuously innovate and differentiate its offerings to maintain market share.
- Changes in consumer preferences and evolving market trends may also pose threats to the company's success. Rapid shifts in consumer demands or emerging substitutes for cannabis products could have a negative impact on CannaPharmaRx Inc's sales and market position.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.